Healthcare
ProtoKinetix, Incorporated(PKTX)
Live Price
Offline$0.00562
+8.08% today
1Y Change
-36.14%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- +90.0%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ProtoKinetix, Incorporated (PKTX) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 36.1% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +90.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +90.0%, free cash flow +48.7% with operating margin -746.7% and ROIC -145.2%. Valuation already assumes a fairly strong business story at price/sales 43.4. Stock Foundry combines PKTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-746.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +90.0%, while operating margin sits near -746.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.2% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +0.0% | +0.7% | -3.7% |
2026 Mar 26, 2026 | โ | -8.0% | +8.0% | +8.0% |
2025 Jul 28, 2025 | โ | -25.2% | +3.9% | -3.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PKTX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PKTX Max Drawdown
-55.56%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PKTX and SPY.
Company Overview
ProtoKinetix, Incorporated
Other OTC
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry-eye diseases. It has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Marietta, Ohio.
- Leadership
- Michael Richard Guzzetta
- IPO Date
- Apr 22, 2002
- Employees
- 5
- Street Address
- 412 Mulberry Street
- Mailing
- Marietta, OH, 45750
- Region
- Marietta, OH, US
- Reporting Currency
- USD
- Investor Line
- 740 434 5041
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 43.4
- Price/Book
- 8.4
Growth
- Revenue
- 0.0%
- EPS
- +90.0%
- Free Cash Flow
- +48.7%
Profitability
- Gross Margin
- -28.4%
- Operating Margin
- -746.7%
- Net Margin
- -772.8%
- ROE
- -116.3%
- ROIC
- -145.2%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.01
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.